CJRB 101
Alternative Names: CJRB-101Latest Information Update: 26 Dec 2023
At a glance
- Originator CJ Bioscience
- Class Antineoplastics; Bacteria; Immunotherapies
- Mechanism of Action Microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Cancer
Most Recent Events
- 11 Sep 2023 Phase-I/II clinical trials in Cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease, Refractory Metastatic disease) in South Korea (PO) (NCT05877430)
- 02 Jun 2023 CJ Bioscience plans a phase I/II trial in Cancer (Late-stage disease, Refractory metastatic disease, Combination therapy, Inoperable/Unresectable, Second-line or greater therapy, First-line therapy) in September 2023 (NCT05877430)
- 02 Jun 2023 Preclinical trials in Cancer in South Korea (unspecified route) (CJ Bioscience website, June 2023)